BHCM
ESPR

Boulder Hill Capital Management’s Esperion Therapeutics ESPR Stock Holding History

Boulder Hill Capital Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-19,900
Closed -$124K – 161
2022
Q4 		$124K Buy
+19,900
New +$142K 0.1% 117

Other funds holding ESPR

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return

Boulder Hill Capital Management's ESPR Position: Q1 2023 in Review

Boulder Hill Capital Management sold out of Esperion Therapeutics (ESPR) in Q1 2023, closing a stake of 19,900 shares — an estimated $124K sold.

Boulder Hill Capital Management first reported a position in ESPR in Q4 2022 and held it in 1 quarter. The position peaked at $124K in Q4 2022. 164 funds tracked by Wall St. Rank hold ESPR as of Q1 2023.

  • Boulder Hill Capital Management reported no remaining Esperion Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Boulder Hill Capital Management sold 19,900 Esperion Therapeutics shares in Q1 2023, an estimated $124K.
  • Boulder Hill Capital Management first reported a position in Esperion Therapeutics in Q4 2022 and held it in 1 quarter.
  • Boulder Hill Capital Management's Esperion Therapeutics position peaked at $124K in Q4 2022.
  • 164 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2023.

Based on Boulder Hill Capital Management's 13F filing for Q1 2023, filed 12 May 2023.